2月24日天目药业（600671）涨停分析：中药升级、产能扩张、国企改革驱动

Group 1 - The core viewpoint of the article highlights that Tianmu Pharmaceutical's stock reached a closing price of 22.46 yuan on February 24, with a significant increase in trading activity, indicating strong market interest [1] - The stock's surge is attributed to the company's ongoing dual strategy of "premium traditional Chinese medicine + health," with a product matrix including proprietary traditional Chinese medicines and health products [1] - The company is enhancing its production capacity through a 100 million yuan investment in a technical transformation project expected to be operational by the end of 2026, which will significantly increase traditional Chinese medicine extraction capacity [1] Group 2 - The article notes that the company is advancing its eye care product line, with the Pearl Eye Drops undergoing GMP compliance checks and 40 drug registrations completed, enhancing expectations for the resumption of production [1] - The state-owned background of Qingdao, with the actual controller being the Qingdao Laoshan District Finance Bureau, is expected to strengthen the company's position amid anticipated state-owned enterprise reforms and resource integration [1] - On February 24, the net inflow of main funds was 12.25 million yuan, accounting for 6.64% of the total transaction amount, while retail investors showed a net outflow of 9.50 million yuan, indicating varied investor sentiment [1]